Abbott (ABT) Suffers a Larger Drop Than the General Market: Key Insights

Abbott (ABT) recently closed down 1.18% at $132.02, significantly underperforming the broader market and its sector, extending a prior 2.09% lag against the S&P 500's gain. Despite this recent stock weakness, analysts anticipate robust future growth, projecting Q3 2025 EPS to increase 9.65% to $1.25 and revenue by 6.7% to $11.07 billion, contributing to a Zacks Rank #2 (Buy). However, ABT trades at a premium valuation with a Forward P/E of 25.91 and a PEG ratio of 2.54, exceeding industry averages, while its Medical - Products industry ranks in the bottom 37% of all industries.

Analysis

Abbott (ABT) exhibits a notable divergence between its recent market performance and its forward-looking fundamental outlook. The stock recently fell 1.18%, underperforming the S&P 500's 0.33% loss and extending a prior-period 2.09% decline against the index's 4.07% gain. Despite this market weakness, consensus estimates project robust growth, with upcoming quarterly earnings per share (EPS) expected to rise 9.65% to $1.25 and revenue to increase 6.7% to $11.07 billion. Full-year forecasts are similarly strong, anticipating 10.49% EPS growth and 6.56% revenue growth, supported by a slight upward revision in consensus EPS estimates over the past month. However, this growth outlook comes at a premium valuation; ABT trades at a Forward P/E of 25.91 and a PEG ratio of 2.54, both of which are above their respective industry averages of 20.14 and 2.29. This premium exists within the context of a poorly performing Medical - Products industry, which holds a Zacks Industry Rank of 156, placing it in the bottom 37% of all industries and presenting a potential headwind.

Key Decisions for Investors

• Investors should weigh the compelling forward-looking growth, including a projected 10.49% full-year EPS increase and a Zacks #2 (Buy) rating, against the stock's recent underperformance and premium valuation.
• The upcoming earnings report on July 17, 2025, serves as a critical catalyst; meeting the consensus forecast of $1.25 EPS will be essential to justify the current valuation and potentially reverse negative sentiment.
• Consider the potential headwind from the stock's industry, which ranks in the bottom 37% of all sectors, a factor that could temper performance even if company-specific results are strong.